Navigation Links
Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
Date:8/19/2007

Expects To See Substantial Sales Growth Balance of Year

SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), will present at the Noble Financial Equity Conference at 11:30 a.m. EDT on Tuesday, August 21, 2007 at the Charleston Place Hotel in Charleston, South Carolina.

William Spencer, Imagenetix's Chief Executive Officer will provide a 25 minute presentation outlining the science, products, and prospects for the Company. Commenting on the prospects, Mr. Spencer said, "I believe that the imminent publication of our most recent clinical study, for our Celadrin product, will lead to significant growth in our private label and branding business. Our distributor is negotiating with several large multinational companies for sale of the private label products, particularly in the International Market. We expect these sales in addition to our growth in retail sales to generate substantial growth in sales during the balance of the year."

The presentation with streaming video and PowerPoint, will be webcast live on Noble Financial's conference website at http://www.two-007.net. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.

About Imagenetix

Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marked globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit, http://www.imagenetix.net.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.


'/>"/>
SOURCE Imagenetix, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2020)... ... June 25, 2020 , ... With the ... vaccine or drug treatment. In an effort to better understand the cellular responses ... world’s largest imaging dataset portraying therapeutic compound effects from over 1,600 approved and ...
(Date:6/28/2020)... , ... June 26, 2020 , ... ... representing security solutions providers, today announced its strong opposition to the recently introduced ... would impose a blanket ban on most federal use of nearly all biometric ...
(Date:6/23/2020)... ... 23, 2020 , ... DeCurtis Corporation, the premier provider of ... Fournier has been appointed CEO and President. Founder and former CEO, David DeCurtis, ... “DeCurtis Corporation has been on an incredible journey for the last twenty years, ...
(Date:6/23/2020)... ... 2020 , ... Dracen Pharmaceuticals Inc., announced today that two ... the American Association for Cancer Research Virtual meeting. One poster describes the immuno-metabolism ... agent activity in KEAP1 mutant tumor models of NSCLC. , “As ...
Breaking Biology Technology:
(Date:6/19/2020)... ... ... Join experts from Envigo Lauren Klaskala, Project Manager – Custom Transgenic Models ... July 8, 2020 at 11am EDT (4pm BST/UK). , Nuclease-based technologies such as CRISPR ... the genome may be more straightforward, the challenge to create an optimal model for ...
(Date:6/5/2020)... ... June 04, 2020 , ... Murrieta Genomics has announced ... application for simplified sample preparation for Next Generation Genomic Sequencing (NGS) . This ... time, and complexity of sample preparation. , “I have been at the bench for ...
(Date:5/30/2020)... ... May 29, 2020 , ... eInfochips, ... enterprises globally, has collaborated with EchoNous Inc. to develop the cloud-based connected health ... systolic heart function, which has been clinically tested versus expert measurements, yielding improved ...
Breaking Biology News(10 mins):